NCT06925724 - A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 4, 2027

Conditions

Endometrial CancerCervical Cancer

Interventions

DRUG

Ivonescimab

Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes)

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale